قارن الطرق

	استبيان أمراض الجهاز التنفسي المزمنة (CRQ)	مقياس مجلس البحوث الطبية لضيق التنفس
المجال	طب الرئة	طب الرئة
العائلة	Process / pipeline	Process / pipeline
سنة النشأة	1987	1959
صاحب الطريقة	Gordon H. Guyatt, McMaster University	Medical Research Council (UK)
النوع	Self-report or interviewer-administered questionnaire	Clinician or self-rated ordinal scale
المصدر التأسيسي	Guyatt, G. H., Berman, L. B., Townsend, M., Pugsley, S. O., & Chambers, L. W. (1987). A measure of quality of life for clinical trials in chronic lung disease. Thorax, 42(10), 773-778.	Van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988). Interobserver agreement for the assessment of handicap in stroke patients. Stroke, 19(5), 604-607.
الأسماء البديلة	CRQ, Chronic Respiratory Q	MRC, MRC Dyspnea, Modified Borg
ذات صلة	5	5
الملخص	The CRQ is a 20-item, four-domain questionnaire developed by Guyatt and colleagues at McMaster University in 1987 to measure health-related quality of life specifically in patients with chronic respiratory disease, particularly chronic obstructive pulmonary disease and cystic fibrosis. Uniquely, the CRQ can be administered by interview or self-report, and its four domains (dyspnea, fatigue, emotional function, mastery) directly address the multidimensional burden of chronic respiratory disease. The CRQ has demonstrated exceptional responsiveness to pulmonary rehabilitation and other interventions, making it a preferred outcome measure in respiratory research and clinical practice.	The MRC Dyspnoea Scale is a simple 5-grade ordinal classification of dyspnea severity based on the exertional threshold at which breathlessness limits activity. Developed by the UK Medical Research Council (MRC) in 1959, it remains one of the most widely used dyspnea assessments globally due to its brevity, ease of administration, and strong prognostic correlation in chronic obstructive pulmonary disease and other chronic respiratory diseases. The scale is used in clinical practice, epidemiological surveys, and longitudinal disease monitoring to grade symptom severity and guide treatment intensity.